4-aminopyridine has been researched along with Atherosclerotic Parkinsonism in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, CS | 1 |
| Wang, GH | 1 |
| Chuang, HH | 1 |
| Chuang, AY | 1 |
| Yeh, JY | 1 |
| Lai, YC | 1 |
| Yang, YC | 1 |
| Haghdoost-Yazdi, H | 2 |
| Piri, H | 1 |
| Najafipour, R | 1 |
| Faraji, A | 2 |
| Fraidouni, N | 2 |
| Dargahi, T | 1 |
| Alipour Heidari, M | 1 |
| Movahedi, M | 1 |
| Hadibeygi, E | 1 |
| Vaezi, F | 1 |
| Kearney, JA | 1 |
| Albin, RL | 1 |
4 other studies available for 4-aminopyridine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Conveyance of cortical pacing for parkinsonian tremor-like hyperkinetic behavior by subthalamic dysrhythmia.
Topics: 4-Aminopyridine; 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepro | 2021 |
Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model.
Topics: 4-Aminopyridine; Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug | 2017 |
Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
Topics: 4-Aminopyridine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Drug Interactions; | 2011 |
Intrasubthalamic nucleus metabotropic glutamate receptor activation: a behavioral, Fos immunohistochemical and [14C]2-deoxyglucose autoradiographic study.
Topics: 4-Aminopyridine; Amino Acids, Dicarboxylic; Animals; Antimetabolites; Autoradiography; Behavior, Ani | 2000 |